Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
Rhea-AI Summary
Propanc Biopharma (Nasdaq: PPCB) announced preclinical results for its lead proenzyme therapy PRP, reporting >85% tumor growth inhibition in pancreatic cancer models and plans for Phase 1b First‑In‑Human trials in 2026. The company cited PRP's chemo‑sensitizing effects, reduced fibrosis, stem‑cell targeting, and a $100M facility to support development.
Propanc positions PRP as a potential therapy for advanced solid tumors with initial focus on pancreatic and ovarian cancers; human efficacy and regulatory outcomes remain pending.
Positive
- >85% tumor growth inhibition in preclinical pancreatic models
- Phase 1b First‑In‑Human trials scheduled for 2026
- $100M facility reportedly in place to support development
- Chemo sensitization and reduced fibrosis observed preclinically
Negative
- No human efficacy data yet; results are preclinical
- Clinical and regulatory outcomes are pending and uncertain
News Market Reaction – PPCB
In the Mar 12 session, PPCB declined 13.57%, reflecting a significant negative market reaction. Argus tracked a peak move of +6.8% during that session. Argus tracked a trough of -23.0% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. Trading volume was very high at 3.0x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | Clinical assay prep | Positive | -20.5% | FyoniBio agreement to develop LC‑MS PK assay for Phase 1b study. |
| Mar 03 | Preclinical efficacy | Positive | -5.2% | Highlighted >85% tumor inhibition and plans for 2026 first‑in‑human trial. |
| Feb 18 | Corporate update | Neutral | -4.5% | Half‑year results, IP expansion, and up to $100M private placement facility. |
| Feb 05 | PRP unveiling | Positive | +5.7% | Positioned PRP as game‑changing therapy for multi‑billion pancreatic market. |
| Jan 27 | IP expansion | Positive | +6.5% | Filed fourth provisional patent to strengthen PRP formulation protection. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent PRP and corporate updates have generally been positive but often met with selling pressure, though earlier IP and PRP unveil news saw upside, indicating mixed follow-through on good news.
Over the last few months, Propanc has repeatedly highlighted PRP’s potential and advanced towards first‑in‑human studies. Since Jan 27, 2026, it expanded IP protection and linked this to a planned Phase 1b trial. On Feb 5 and Mar 3, the company underscored >85% tumor inhibition and market potential. A Mar 10 assay deal with FyoniBio supported 2026 trial readiness. Today’s announcement reiterates these efficacy themes and positions PRP within the pancreatic cancer opportunity.
Key Terms
proenzyme therapy medical
tumor microenvironment medical
cancer stem cells medical
Phase 1b regulatory
first-in-human regulatory
chemo sensitization medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Root-Cause Attack. Chemo Sensitization. Safer Profile.
MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced highlights of PRP, its lead proenzyme therapy poised to potentially disrupt the
Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game:
- >
- Forces malignant cells to differentiate—attacking cancer at its root
- Reduces fibrosis and resistance markers in the tumor microenvironment
- Sensitizes resistant tumors to standard chemo—higher efficacy, lower toxicity
- Targets cancer stem cells to cut recurrence risk
“PRP may represent a true paradigm shift for pancreatic cancer patients,” said Mr. James Nathanielsz, Propanc’s Chief Executive Officer. “We’re striking at the disease’s core mechanisms. With Phase 1b First-In-Human trials set for 2026 and a
Propanc is advancing PRP toward clinical development for advanced solid tumors, with pancreatic and ovarian cancers as initial priorities.
Learn more: www.propanc.com
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Investor Contact:
irteam@propanc.com
